Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...

Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago. Its total revenue for the ...

Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/100.CtMQo59V.js ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Liberty Mutual Investments—the investment firm of Liberty Mutual Group of Insurance Cos.—is building on an existing partnership with Affirm. Over the program term, through June 2027, the investment ...

Novo Nordisk’s phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Investing.com - Copenhagen-listed shares in Novo Nordisk (CSE: NOVOb) surged on Friday after the Danish drugmaker said ...